NCT04926103 Screening Donors, Fecal Microbiota Transplant Program in Ulcerative Colitis
| NCT ID | NCT04926103 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Hamilton Health Sciences Corporation |
| Condition | Ulcerative Colitis Flare |
| Study Type | INTERVENTIONAL |
| Enrollment | 200 participants |
| Start Date | 2022-07-01 |
| Primary Completion | 2028-10-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 200 participants in total. It began in 2022-07-01 with a primary completion date of 2028-10-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The investigators intend to screen for new donors, given that there may a donor effect (PubMed ID: 25857665), with some donors not inducing remission in any patient whilst others inducing remission in 20-40% of cases. It is important to give UC patients participating in RCTs stool that has been demonstrated to be effective in some patients. We therefore propose to conduct an open label study in patients with active UC to ensure new donors are effective at inducing remission in some patients. Patients that have FMT will relapse within 18 months (PubMed ID: 25857665) although further FMT therapy induces remission so it is possible that maintenance FMT will result in long term remission, but this needs evaluation. We will therefore follow UC patients that have responded to FMT long term in this open label study.
Eligibility Criteria
Inclusion Criteria: 1. Patients aged 18 or over 2. Active UC defined as a Mayo score (7) \>3 3. A Mayo endoscopic score (7) \>0 4. Females of child-bearing potential must be willing and able to use acceptable contraception as per Appendix III. II. b. Toxicity section of the Health Canada Guidance Exclusion Criteria: 1. Participating in another intervention study for UC 2. Unable to give informed consent 3. Severe comorbid medical illness 4. Severe UC requiring hospitalization. 5. Increase in medical therapy for UC in the last 12 weeks. Continued treatment with 5-ASA, azathioprine, 6-mercaptopurine or anti-TNF therapy (e.g. infliximab) will be permitted if taken at stable dose for ≥12 weeks prior to randomization. Relapse on a stable dose (same dose for at least 2 weeks) or a tapering dose of steroids will also be permitted provided the dose of steroid is not increased again. Stable intake of probiotic therapy also permitted. 6. Antibiotic therapy in the last 30 days. 7. Pregnant women. 8. Patients with clinically significant hepatic dysfunction at the time of screening: ALT \> 5 times the upper normal range. 9. Patients with clinically significant renal dysfunction at the time of screening: serum creatinine \> 300 µmol/L 10. Any condition, in the opinion of the investigator, that the treatment may pose a health risk to the subject.
Contact & Investigator
Paul Moayyedi, MD
PRINCIPAL INVESTIGATOR
HHSC/McMaster
Frequently Asked Questions
Who can join the NCT04926103 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Ulcerative Colitis Flare. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04926103 currently recruiting?
Yes, NCT04926103 is actively recruiting participants. Contact the research team at wolfe@hhsc.ca for enrollment information.
Where is the NCT04926103 trial being conducted?
This trial is being conducted at Hamilton, Canada.
Who is sponsoring the NCT04926103 clinical trial?
NCT04926103 is sponsored by Hamilton Health Sciences Corporation. The principal investigator is Paul Moayyedi, MD at HHSC/McMaster. The trial plans to enroll 200 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.